'Super-antibodies' could curb COVID-19 and help avert future pandemics
Elie Dolgin • June 22, 2021
Companies are designing next-generation antibodies modeled on those taken from unique individuals whose immune systems can neutralize any COVID-19 variant — and related coronaviruses, too.
The US Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) in late May to sotrovimab, providing a new therapeutic weapon in the fight against SARS-CoV-2—and future coronaviruses with pandemic potential.
According to analysts and researchers alike, so-called super-antibodies such as sotrovimab should have an edge over first-generation monoclonal antibody (mAb) therapies for COVID-19 because of their broad neutralization capacity in the face of emerging virus variants.
Continue reading at Nature Biotechnology.
Pixels meet paint, as a digital “mask” conceals damage on a 15th-century painting.
Options are emerging for the tens of millions of people who stop taking GLP-1 drugs because of side effects, cost or availability.